July 2025
1. ELSAYED AMA, Kurose M, Higashiura A, Yamamoto A, et al
   Suppression of herpes simplex virus type 1 replication by Pin1 inhibitors: insights from H-77 and novel compounds.
   Antiviral Res. 2025;241:106244.
   

   >> Share

   
   March 2025
2. BIRKMANN A, Saunders R
   Overview on the management of herpes simplex virus infections: Current therapies and future directions.
   Antiviral Res. 2025;237:106152.
   

   >> Share

   
   November 2024
3. HU Z, Liu W, Liu J, Zhou H, et al
   The anti-tumor efficacy of a recombinant oncolytic herpes simplex virus mediated CRISPR/Cas9 delivery targeting in HPV16-positive cervical cancer.
   Antiviral Res. 2024 Nov 11:106035. doi: 10.1016/j.antiviral.2024.106035.
   

   >> Share

   
   August 2024
4. SZEMERE ZK, Murphy EA
   Import of extracellular 2'-3'cGAMP by the folate transporter, SLC19A1, establishes an antiviral response that limits Herpes Simplex Virus-1.
   Antiviral Res. 2024 Aug 16:105989. doi: 10.1016/j.antiviral.2024.105989.
   

   >> Share

   
   
5. ZHENG S, Verjans GMGM, Evers A, van den Wittenboer E, et al
   CRISPR/Cas9-mediated genome editing of the thymidine kinase gene in a clinical HSV-1 isolate identifies F289S as novel acyclovir-resistant mutation.
   Antiviral Res. 2024;228:105950.
   

   >> Share

   
   June 2024
6. PEI J, Tian Y, Dang Y, Ye W, et al
   Flexible nano-liposomes-encapsulated recombinant UL8-siRNA (r/si-UL8) based on bioengineering strategy inhibits herpes simplex virus-1 infection.
   Antiviral Res. 2024;228:105936.
   

   >> Share

   
   
7. CHEN SH, Damborsky JC, Wilson BC, Fannin RD, et al
   alpha7 Nicotinic Receptor Activation Mitigates Herpes Simplex Virus Type 1 Infection in Microglia Cells.
   Antiviral Res. 2024 Jun 14:105934. doi: 10.1016/j.antiviral.2024.105934.
   

   >> Share

   
   May 2024
8. EL-MAYET FS, Santos VC, Wijesekera N, Lubbers S, et al
   Glucocorticoid receptor and specificity protein 1 (Sp1) or Sp3, but not the antibiotic Mithramycin A, stimulates human alphaherpesvirus 1 (HSV-1) replication.
   Antiviral Res. 2024;225:105870.
   

   >> Share

   
   November 2023
9. BERNSTEIN DI, Sawtell NM, Bravo FJ, Dixon DA, et al
   Intermittent therapy with helicase-primase inhibitor IM-250 efficiently controls recurrent herpes disease and reduces reactivation of latent HSV.
   Antiviral Res. 2023;219:105733.
   

   >> Share

   
   August 2023
10. GIORGI J, Simon B, Destras G, Semanas Q, et al
    Novel UL23 and UL30 substitutions in HSV1 and HSV2 viruses related to polymorphism or drug resistance.
    Antiviral Res. 2023;216:105672.
    

    >> Share

    
    July 2023
11. FENG Y, Yang Y, Zou S, Qiu S, et al
    Identification of alpha-linolenic acid as a broad-spectrum antiviral against zika, dengue, herpes simplex, influenza virus and SARS-CoV-2 infection.
    Antiviral Res. 2023 Jul 8:105666. doi: 10.1016/j.antiviral.2023.105666.
    

    >> Share

    
    May 2023
12. CIVRA A, Costantino M, Ronchi G, Pontini L, et al
    Identification of oxysterol synthetic analogs as a novel class of late-stage inhibitors of herpes simplex virus 2 replication.
    Antiviral Res. 2023;215:105634.
    

    >> Share

    
    
13. PACHOTA M, Grzywa R, Iwanejko J, Synowiec A, et al
    Novel inhibitors of HSV-1 protease effective in vitro and in vivo.
    Antiviral Res. 2023;213:105604.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share